Journal
CLINICAL & TRANSLATIONAL ONCOLOGY
Volume 11, Issue 1, Pages 54-59Publisher
SPRINGER INTERNATIONAL PUBLISHING AG
DOI: 10.1007/s12094-009-0311-4
Keywords
Anthracycline; Breast carcinoma; Primary chemotherapy; Sequential; Taxane; Weekly
Categories
Funding
- Sanofi-Aventis
Ask authors/readers for more resources
To evaluate the sequential administration of doxorubicin (A) and cyclophosphamide (C) followed by weekly docetaxel in women with stage II to IIIA breast cancer. Patients received 60 mg/m(2) of A and 600 mg/m(2) of C every three weeks for four cycles followed by 12 infusions of weekly docetaxel at a dose of 36 mg/m(2) and with a 2-week resting period. Sixty-three women were included. On an intentionto-treat basis, clinical response rate was 90% (95% CI: 83-98), with 46% complete responses. Breast-conserving surgery could be performed in 43 patients (68%). Complete pathological responses in the breast were confirmed in 17% of patients. No correlations between levels of expression of topoisomerase II alpha, survivin or p27 and the pathological response were detected. The study treatment was generally well tolerated. Neoadjuvant AC followed by weekly docetaxel is a feasible regimen for patients with early-stage breast cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available